This did not appear to be through changes to signal bias, as BETP at this dose did not affect cAMP or -arrestin-2 recruitment responses (Fig
Specialist supervision is required, and patients should discuss potential risks and interactions with their physician before starting any GLP-1 microdosing protocol
Conclusions In this large cohort study, the use of GLP-1 receptor agonists was not associated with an increased risk of suicidality compared with the use of DPP-4 inhibitors or SGLT-2 inhibitors in patients with type 2 diabetes
Semaglutide is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Common Adverse Effects According to clinical trial data, gastrointestinal effects are most frequently reported: nausea, vomiting, diarrhea, constipation, and abdominal discomfort
The concept differs fundamentally from how prescription GLP-1 receptor agonists work